Antineoplaston A 10

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530008

CAS#: 91531-30-5

Description: Antineoplaston A 10 is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.

Chemical Structure

img
Antineoplaston A 10
CAS# 91531-30-5
Instruction

Theoretical Analysis

MedKoo Cat#: 530008
Name: Antineoplaston A 10
CAS#: 91531-30-5
Chemical Formula: C13H14N2O3
Exact Mass: 246.10
Molecular Weight: 246.270
Elemental Analysis: C, 63.40; H, 5.73; N, 11.38; O, 19.49

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ANP-A-10; ANPA-10; ANP A 10; ANPA 10;

IUPAC/Chemical Name: N-[(3S)-2,6-dioxopiperidin-3-yl]-2-phenylacetamide

InChi Key: OQGRFQCUGLKSAV-JTQLQIEISA-N

InChi Code: InChI=1S/C13H14N2O3/c16-11-7-6-10(13(18)15-11)14-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,17)(H,15,16,18)/t10-/m0/s1

SMILES Code: O=C(N[C@@H](CC1)C(NC1=O)=O)CC2=CC=CC=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 246.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Qu XJ, Cui SX, Tian Z, Li X, Chen MH, Xu WF, Inagaki Y, Deng YB, Makuuchi M,
Nakata M, Tang W. Induction of apoptosis in human hepatocellular carcinoma cells
by synthetic antineoplaston A10. Anticancer Res. 2007 Jul-Aug;27(4B):2427-31.
PubMed PMID: 17695534.

2: Burzynski SR, Lewy RI, Weaver RA, Axler ML, Janicki TJ, Jurida GF, Paszkowiak
JK, Szymkowski BG, Khan MI, Bestak M. Phase II study of antineoplaston A10 and
AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a
preliminary report. Drugs R D. 2003;4(2):91-101. PubMed PMID: 12718563.

3: Burzynski SR, Weaver RA, Lewy RI, Janicki TJ, Jurida GF, Szymkowski BG, Khan
MI, Bestak M. Phase II study of antineoplaston A10 and AS2-1 in children with
recurrent and progressive multicentric glioma : a preliminary report. Drugs R D.
2004;5(6):315-26. PubMed PMID: 15563234.

4: Badria F, Mabed M, El-Awadi M, Abou-Zeid L, Al-Nashar E, Hawas S. Immune
modulatory potentials of antineoplaston A-10 in breast cancer patients. Cancer
Lett. 2000 Aug 31;157(1):57-63. PubMed PMID: 10893443.

5: Badria F, Mabed M, Khafagy W, Abou-Zeid L. Potential utility of antineoplaston
A-10 levels in breast cancer. Cancer Lett. 2000 Jul 3;155(1):67-70. PubMed PMID:
10814881.

6: Tsuda H, Iemura A, Sata M, Uchida M, Yamana K, Hara H. Inhibitory effect of
antineoplaston A10 and AS2-1 on human hepatocellular carcinoma. Kurume Med J.
1996;43(2):137-47. PubMed PMID: 8755117.

7: Fujii T, Nakamura AM, Yokoyama G, Yamaguchi M, Tayama K, Miwa K, Toh U,
Kawamura D, Shirouzu K, Yamana H, Kuwano M, Tsuda H. Antineoplaston induces G(1)
arrest by PKCalpha and MAPK pathway in SKBR-3 breast cancer cells. Oncol Rep.
2005 Aug;14(2):489-94. PubMed PMID: 16012735.

8: Kumabe T, Tsuda H, Uchida M, Ogoh Y, Hayabuchi N, Sata M, Nakashima O, Hara H.
Antineoplaston treatment for advanced hepatocellular carcinoma. Oncol Rep. 1998
Nov-Dec;5(6):1363-7. PubMed PMID: 9769368.

9: Choi BG, Kim OY, Chung BH, Cho WJ, Cheon SH, Choi SU, Lee CO. Synthesis of
antineoplaston A10 analogs as potential antitumor agents. Arch Pharm Res. 1998
Apr;21(2):157-63. PubMed PMID: 9875424.

10: Choi BG, Seo HK, Chung BH, Choi SU, Lee CO. Synthesis of Mannich bases of
antineoplaston A10 and their antitumor activity. Arch Pharm Res. 1994
Dec;17(6):467-9. PubMed PMID: 10319160.

11: Ogata Y, Matono K, Shirouzu K. [Anti-proliferative effects of biochemical
defense modifier antineoplaston in colorectal carcinoma]. Nihon Rinsho. 2003
Sep;61 Suppl 7:505-9. Japanese. PubMed PMID: 14574945.

12: Ashraf AQ, Liau MC, Kampalath BN, Burzynski SR. Pharmacokinetic study of
radioactive antineoplaston A10 following oral administration in rats. Drugs Exp
Clin Res. 1987;13 Suppl 1:45-50. PubMed PMID: 3569015.

13: Ogata Y, Matono K, Tsuda H, Ushijima M, Uchida S, Akagi Y, Shirouzu K.
Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or
without antineoplastons as an adjuvant therapy after hepatectomy for liver
metastases from colorectal cancer. PLoS One. 2015 Mar 19;10(3):e0120064. doi:
10.1371/journal.pone.0120064. PubMed PMID: 25790229; PubMed Central PMCID:
PMC4366171.

14: Michalska D. Theoretical investigations on the structure and potential
binding sites of antineoplaston A10 and experimental findings. Drugs Exp Clin
Res. 1990;16(7):343-9. PubMed PMID: 2092960.

15: Tsuda H. Inhibitory effect of antineoplaston A-10 on breast cancer
transplanted to athymic mice and human hepatocellular carcinoma cell lines. The
members of Antineoplaston Study Group. Kurume Med J. 1990;37(2):97-104. PubMed
PMID: 2175003.

16: Tsuda H, Sugihara S, Nishida H, Hara H, Eriguchi N, Ishii K, Sasaki K,
Yoshimura S, Tanaka N. The inhibitory effect of the combination of antineoplaston
A-10 injection with a small dose of cis-diamminedichloroplatinum on cell and
tumor growth of human hepatocellular carcinoma. Jpn J Cancer Res. 1992
May;83(5):527-31. PubMed PMID: 1377669.

17: Ashraf AQ, Liau MC, Mohabbat MO, Burzynski SR. Preclinical studies on
antineoplaston A10 injections. Drugs Exp Clin Res. 1986;12 Suppl 1:37-45. PubMed
PMID: 3743379.

18: Xu W, Wang H, Yuan Y. Pharmacokinetic study of radioactive antineoplaston A10
in rats and mice. Drugs Exp Clin Res. 1990;16(7):351-5. PubMed PMID: 2092961.

19: Muldoon TG, Copland JA, Lehner AF, Hendry LB. Inhibition of spontaneous mouse
mammary tumour development by antineoplaston A10. Drugs Exp Clin Res. 1987;13
Suppl 1:83-8. PubMed PMID: 3569021.

20: Wang H, Xu W, Yuan Y. Studies of the release rate and bioavailability of
antineoplaston A10 capsule. Drugs Exp Clin Res. 1990;16(7):357-9. PubMed PMID:
2092962.